# A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

> **NCT05859217** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jun Zhang, MD, PhD** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer
- NSCLC Stage IV
- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Advanced NSCLC

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05859217
- **Lead sponsor:** Jun Zhang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859217, "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05859217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*